drugset / Trial / NCT05238532
Clinical Trial to Evaluate the Safety, Tolerability and Efficacy of CT303 in Patients With ARDS
NaSingle-groupOpen-labelTreatment
Summary
Evaluate the safety, tolerability, efficacy and pharmacodynamics\&pharmacokinetic properties of CT303 in patients with ARDS.
Timeline
- Start
- 2022-01-26
- Primary completion
- 2023-02-22
- Completion
- 2023-02-22
Outcome
Outcome not reported
Stopped (Enrollment): “Difficulties in recruiting Subjects”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CT303 | Cell therapy | 1e+06 cells/kg | Intravenous |
| Subject | CT303 | Cell therapy | 2e+06 cells/kg | Intravenous |